Corporate Overview

Established in 2017, Elpis is a pre-clinical stage biopharmaceutical company.

Our vision is to become a leading biotech company by developing innovative biological and cellular therapeutics for difficult-to-treat cancers.

Through our proprietary antibody discovery and protein engineering platforms, we are advancing a rich pipeline to treat solid tumors and hematological malignancies with the goal of improving outcomes for patients with difficult-to-treat and resistant cancers.

Our strategy includes:

  • Develop and commercialize wholly owned programs
  • Collaboration or out-licensing of pipeline program
  • Research collaborations to discover lead candidates for partner’s preferred targets

Locations in USA and China